Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Introduction The purpose of this study was to compare age-related differences in osteoprotegerin (OPG) in relationship with BMD and the serum bone markers osteocalcin (OC), collagen crosslinks (CTX), and tartrate-resistant acid phosphatase 5b (TRACP-5b).Methods Data were derived from a cross-sectional study on bone health in a random sample of community-dwelling adults aged 30 to 85 years in the Reykjavik area in Iceland. All subjects had whole body, hip, and lumbar spine BMD measured (by DXA), gave blood samples, and answered a thorough questionnaire on medications and medical history. We assessed relationships using the Spearman correlation coefficient, partial correlation, and multivariable linear regression. Men and women were analyzed separately.Results Of 2,310 subjects invited over 2 years, 1,630 participated. After excluding individuals with diseases and medications affecting bone metabolism, 517 women (age 56.1 +/- 16.9 years) and 491 men (age 58.7 +/- 14.9 years) remained for analysis. OPG increased steadily with age in both genders without a gender difference. In women, BMD at all sites declined steadily after age 50. In men, BMD remained relatively stable until age 70, after which it declined significantly. After controlling for age, BMI, and other confounding variables, OPG showed only a borderline positive relationship with whole body BMD in men (P = 0.10), but the relationship was nonsignificant in women. In multivariable models, OPG was inversely related to TRACP-5b (P = 0.002) and positively with OC (P = 0.007), the OC/TRACP-5b (P = 0.001) and OC/CTX (P = 0.02) ratios in women. Among men, multivariable models showed a positive association between OPG and OC (P = 0.05) and OC/TRACP-5b (P < 0.009).Conclusions We conclude that serum OPG levels are associated with a profile of bone turnover markers favoring bone formation, suggesting that OPG may be protective against age-related bone loss. Longitudinal studies are needed to address that issue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [372]
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [372]
In the citing paper
“OPG levels in men have been correlated inversely with BMD (373, 392), borderline positively with BMD (372), or not at all (376).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [372]
In the citing paper
“As with women, serum OPG levels increase with age in men (372,373,376,380,381,391,392).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [372]
In the citing paper
“Age appears to be a major factor influencing OPG levels in nearly all studies (372-377).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [372]
Citations
Cites
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Södergard, R., Bäckström, T., Shanbhag, V., & Carstensen, H. (1982) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(82)90038-3 · Cited by 1,080
The Use of Biochemical Markers of Bone Turnover in Osteoporosis
Delmas, P. D., Eastell, R., Garnero, P., Seibel, M. J., & Stepan, J. (2000) · Osteoporosis International · doi:10.1007/s001980070002 · Cited by 722
Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 1×
“, sex hormones and PTH, may exert their effect on bone through OPG as suggested by more direct studies [29, 30, 31, 32, 33, 34, 35, 36].”
ResultHernandez, C. J., Beaupr�, G. S., & Carter, D. R. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1454-8 · Cited by 570
Browner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464
Changes in Bone Mineral Density with Age in Men and Women: A Longitudinal Study
Warming, L., Hassager, C., & Christiansen, C. (2002) · Osteoporosis International · doi:10.1007/s001980200001 · Cited by 382
Yano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363
Kurland, E. S., Cosman, F., McMahon, D. J., Rosen, C. J., Lindsay, R., & Bilezikian, J. P. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6818 · Cited by 360
Aubin, J. E., & Bonnelye, E. (2000) · Osteoporosis International · doi:10.1007/s001980070028 · Cited by 319
Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9394 · Cited by 311
Heaney, R. P. (2003) · Bone · doi:10.1016/s8756-3282(03)00236-9 · Cited by 306
Nguyen, T. V., Center, J. R., & Eisman, J. A. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.2.322 · Cited by 290
Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status1
Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., & Delmas, P. D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7657 · Cited by 234
Eastell, R., Robins, S. P., Colwell, T., Assiri, A. M. A., Riggs, B. L., & Russell, R. G. G. (1993) · Osteoporosis International · doi:10.1007/bf01623829 · Cited by 210
Correlates of osteoprotegerin levels in women and men.
Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L. (2002) · Osteoporosis International · doi:10.1007/s001980200045 · Cited by 205 · cited 5×
“In another study, a strong independent positive association between OPG and BMD was found in cardiac transplant patients [15]; however, several other studies have not demonstrated an association between OPG and BMD [8, 10, 12, 13, 14].”
BackgroundResultInfluentialRogers, A., Saleh, G., Hannon, R. A., Greenfield, D., & Eastell, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020396 · Cited by 200 · cited 2×
“For example, no association [12], an inverse relationship [13], and a positive correlation [9] have been found between OPG and estrogen levels in women.”
BackgroundResultHormonal and Biochemical Parameters in the Determination of Osteoporosis in Elderly Men*
Center, J. R., Nguyen, T. V., Sambrook, P. N., & Eisman, J. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6051 · Cited by 189
Serum levels of osteoprotegerin increase with age in a healthy adult population.
Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187
Vidal, N., Brandstrom, H., Jonsson, K., & Ohlsson, C. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1590191 · Cited by 185 · cited 1×
“, sex hormones and PTH, may exert their effect on bone through OPG as suggested by more direct studies [29, 30, 31, 32, 33, 34, 35, 36].”
ResultSoluble RANKL and risk of nontraumatic fracture.
Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146 · cited 2×
“Another study observed an increased risk of nontraumatic fractures in subjects with low serum levels of RANK-Ligand, OPG levels were not associated with such a risk but the ratio of the two was not examined [16].”
BackgroundResultRegulation of Osteoprotegerin mRNA Levels by Prostaglandin E2in Human Bone Marrow Stroma Cells
Brändström, H., Jonsson, K. B., Ohlsson, C., Vidal, O., Ljunghall, S., & Ljunggren, Ö. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8783 · Cited by 144
Fazzalari, N. L., Kuliwaba, J. S., Atkins, G. J., Forwood, M. R., & Findlay, D. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.6.1015 · Cited by 129 · cited 1×
“and both bone formation and resorption [37].”
Marcus, R., Holloway, L., Wells, B., Greendale, G., James, M. K., Wasilauskas, C., & Kelaghan, J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1583 · Cited by 114
Brändström, H., Jonsson, K. B., Vidal, O., Ljunghall, S., Ohlsson, C., & Ljunggren, Ö. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8993 · Cited by 113
Viereck, V., Gründker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K.-H., Raddatz, D., Emons, G., & Hofbauer, L. C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021877 · Cited by 110
New anabolic therapies in osteoporosis
Rubin, M. R., & Bilezikian, J. P. (2003) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(02)00056-7 · Cited by 85
Siddiqi, A., Burrin, J. M., Noonan, K., James, I., Wood, D. F., Price, C. P., & Monson, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3804 · Cited by 83
Hofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72 · cited 1×
“, sex hormones and PTH, may exert their effect on bone through OPG as suggested by more direct studies [29, 30, 31, 32, 33, 34, 35, 36].”
ResultFahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71 · cited 1×
“In another study, a strong independent positive association between OPG and BMD was found in cardiac transplant patients [15]; however, several other studies have not demonstrated an association between OPG and BMD [8, 10, 12, 13, 14].”
ResultSigurðsson, G., Franzson, L., Steingrímsdóttir, L., & Sigvaldason, H. (2001) · Osteoporosis International · doi:10.1007/s001980070024 · Cited by 66
Self-citationFahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62
Bone markers : biochemical and clinical perspectives
Eastell, R. (2001) · Martin Dunitz eBooks · Cited by 55
Minisola, S., Dionisi, S., Pacitti, M. T., Paglia, F., Carnevale, V., Scillitani, A., Mazzaferro, S., Geronimo, S. D., Pepe, J., D'Erasmo, E., et al. (2002) · Osteoporosis International · doi:10.1007/s001980200009 · Cited by 48
Jung, K., Lein, M., Hösslin, K. V., Grosse, A., Roth, S., Possinger, K., & Lüftner, D. (2002) · The International Journal of Biological Markers · doi:10.1177/172460080201700306 · Cited by 23
The effects of fracture or disease on biochemical markers of bone remodelling
Kleerekoper, M. (2024) · CRC Press eBooks · doi:10.1201/9781003579472-15 · Cited by 1
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Jorde, R., Sneve, M., Torjesen, P. A., Figenschau, Y., Hansen, J.-B., & Grimnes, G. (2010) · Nutrition Journal · doi:10.1186/1475-2891-9-1 · Cited by 323
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
KOSTENUIK, P. (2005) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.06.005 · Cited by 281
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“Later larger studies of both men and women reported strong positive associations between serum OPG and age but not with bone density (37, 48).”
BackgroundGoëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
Metadata
- Authors
- Indridason, O. S., Franzson, L., & Sigurdsson, G.
- Affiliations
- National University Hospital of Iceland (IS)
- Corresponding author
- Sigurdsson, Gunnar
- ORCID
- Franzson, Leifur
- Venue
- Osteoporosis International
- Published
- 2004-07-20
- Volume
- 16
- Issue
- 4
- Pages
- 417-423
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2005186658
- Cited by
- 107
- References
- 38
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 4 · 2021: 6 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 4 · 2016: 3 · 2015: 8 · 2014: 2 · 2013: 12 · 2012: 5
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Hirsla (Landspítali University Hospital) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoprotegerin, bone mineral density, bone turnover markers, osteocalcin, collagen cross-links, TRACP-5b, age-related bone loss, sex differences, bone formation, community-dwelling adults
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aging, Cross-Sectional Studies, Female, Glycoproteins, Hip Joint, Humans, Lumbar Vertebrae, Male, Middle Aged, Sex Characteristics, Biomarkers, Bone Density, Bone Remodeling, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.